News

The approval is based on the ADVANCE-2 and ADVANCE-3 clinical trials, part of the EXPANSE clinical trial program. ELIQUIS is an oral anticoagulant with a 12- to 24-hour

PinAAcle series’ configuration allows for compact design in applications like environmental regulations for drinking water, clinical usage in customer-validated applications such as screening for lead, and requirements of

The latest facility is one of a network of six global RD&I centers that work with the company’s businesses . The six global RD&I centers host a combination

The CHMP’s opinion was for the combination of Victrelis with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have

Xiapex is a new non-surgical injectable treatment option for Dupuytren’s contracture in adult patients with a palpable cord. So far, Pfizer has paid $52.5m of regulatory milestones to

According to the latest move, the maximum allowable dosage of the drug for CPP changes from 90µg/kg/4 weeks to 180µg/kg/4 weeks. The Committee on Drug I, Pharmaceutical Affairs

The Phase 2 trial will assess the anti-tumor activity, tolerability and safety of retaspimycin HCl in combination with docetaxel as compared to docetaxel alone in approximately 100 second-

UST claims its PBV process technology makes it possible to achieve higher yields after drying and better stability during storage at ambient or even higher temperatures (including 37°C

The main objective of the trial is to assess the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for